Search clinical trials for: anti-PD-1

Total 131595 results

Groupe Hospitalier Pitie-Salpetriere
Institut National de la Santé Et de la Recherche Médicale, France

Completed

Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction (CHIMeRA)

Autoimmune Diseases | Endocrine System Diseases | Cancer | Arthritis | Myositis | Neuropathy | Cardiac Disease | Ophthalmopathy

France
Southeast University, China

Unknown

Immunoregulatory Therapy for 2019-nCoV

2019 nCoV, PD-1
Sun Yat-sen University
Chipscreen Biosciences, Ltd.

Not yet recruiting

Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR) (PCR)

Relapsed or Refractory DLBCL
Sun Yat-sen University

Recruiting

Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer

Endometrial Cancer

China
Hunan Cancer Hospital

Completed

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer

Metastatic Colorectal Adenocarcinoma

China
Chinese PLA General Hospital

Unknown

A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas

Lymphoma | Solid Tumor

China
Themis Bioscience GmbH
Assign Data Management and Biostatistics GmbH; Optimapharm

Withdrawn

A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract

Gastrointestinal Cancer

Germany
Northwestern University
National Cancer Institute (NCI)

Recruiting

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

Locally Advanced Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Oncocytic Carcinoma

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection

Hepatocellular Carcinoma | Graft Rejection | Immunotherapy | Immune Checkpoint Inhibitor

China
Yancheng First People's Hospital

Recruiting

Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors

Solid Tumors

China
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

Relapsed/Refractory Peripheral T-cell Lymphoma

China
University Hospital, Ghent
Jessa Hospital; University Hospital, Antwerp; AZ Sint-Jan AV; AZ Delta; General Hospital... and other collaborators

Terminated

BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs (BLOOD)

Melanoma | Cancer

Belgium
Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute

Completed

Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

Malignant Solid Tumour

China
Novita Pharmaceuticals, Inc.

Recruiting

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Advanced or Metastatic Solid Tumor Malignancies

United States
Guangzhou Gloria Biosciences Co., Ltd.

Recruiting

Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer (CC)

Cervical Cancer

China
Guangzhou Gloria Biosciences Co., Ltd.

Completed

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
LI XIN-XIANG

Not yet recruiting

A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis (Miracle-2)

Advanced Rectal Cancer | Distal Metastasis

China
Sun Yat-sen University

Recruiting

Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

China
BeiGene

Active, not recruiting

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Locally Advanced and Metastatic Solid Tumors

China, Taiwan, United States, Australia
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Completed

Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

United States
Fudan University
Shanxi Province Cancer Hospital; Inner Mongolia Cancer Hospital Affiliated...

Recruiting

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Advanced Thyroid Cancer Patients Who Received Target Therapy

China
ARCAGY/ GINECO GROUP
Tesaro, Inc.

Active, not recruiting

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (ROCSAN)

Ovarian Carcinosarcoma | Endometrial Carcinosarcoma

France
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou Anjie Biomedical Technology Co., Ltd.

Completed

PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer

Advanced Breast Cancer | Breast Neoplasm Malignant Female

China
Guangzhou Gloria Biosciences Co., Ltd.

Unknown

Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma

Classical Hodgkin's Lymphoma

China
Groupe Hospitalier Pitie-Salpetriere

Recruiting

JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors (JOCARDITE)

Heart Diseases | Cardiovascular Diseases | Vasculitis | Myocarditis | Cardiomyopathies | Pericarditis

France
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)

Alveolar Soft Part Sarcoma

China
NETRIS Pharma
Centre Leon Berard; Merck Sharp & Dohme LLC

Recruiting

GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab (GYNET)

Endometrial Carcinoma | Cervix Carcinoma

France
Shixiu Wu

Recruiting

Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer

Pancreatic Cancer

China
Akeso

Active, not recruiting

A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors

Advanced or Metastatic Solid Tumors

Australia
Hunan Cancer Hospital

Recruiting

Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

Chemotherapy Effect | NK/T-cell Lymphoma of Nasal Cavity | Immune Checkpoint Inhibitor | Epigenetic Disorder

China
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

High-risk Non-muscle Invasive Bladder Cancer

Canada, Belgium, United States, Australia, Austria, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, China, Brazil, Colombia, ... and more
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)

Bladder Cancer

United States, Spain, United Kingdom, Canada, France, Germany, Italy, Netherlands
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)

Bladder Cancer

United States, Spain, United Kingdom, Canada, France, Germany, Italy, Netherlands
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Peripheral T Cell Lymphoma

China
Meng Chao Hepatobiliary Hospital of Fujian Medical...

Not yet recruiting

A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

Hepatocellular Carcinoma

China
Chinese PLA General Hospital

Completed

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Ovarian Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

Metastatic Melanoma | Advanced Melanoma

China
Shanghai Zhongshan Hospital

Not yet recruiting

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Non-Small Cell Lung Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy (HN)

Head and Neck Cancer

China
Shanghai Henlius Biotech

Recruiting

A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

Gastric Cancer

China
Cliniques universitaires Saint-Luc- Université...

Completed

Side Effects of Anti-PD-(L)-1 and Anti CTLA-A4 in the Non Small Cells Lung Cancer

Carcinoma, Non-Small-Cell Lung | Drug-Related Side Effects and Adverse Reactions

Belgium
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT

Advanced Hepatocellular Carcinoma | Radiotherapy | Sorafenib | Toripalimab

China
Shen Feng

Active, not recruiting

Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC

Intrahepatic Cholangiocarcinoma

China
Lawrence Feldman, MD
Merck Sharp & Dohme LLC; HiberCell, Inc.

Active, not recruiting

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

Non-Small Cell Lung Cancer

United States
Akeso
Akeso Pharmaceuticals, Inc.

Completed

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Chinese PLA General Hospital

Recruiting

Decitabine and Anti-PD-1 in R/R DLBCL

Diffuse Large B Cell Lymphoma | Central Nervous System Lymphoma | Extranodal Extension | Relapse/Recurrence

China
Shanghai Zhongshan Hospital
Sun Yat-sen University; Eastern Hepatobiliary Surgery Hospital

Not yet recruiting

Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

Hepatocellular Carcinoma

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.

Non-small Cell Lung Cancer | Esophageal Squamous Cell Carcinoma

China
Akeso
Akeso Tiancheng, Inc

Completed

A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer

Squamous Cell Lung Cancer | Lung Cancer Non-small Cell Stage IV

China

Search clinical trials for: anti-PD-1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations